An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment

Transfusion

Volumn 50, Issue 6, 2010, Pages 1210-1219

  Cazenave, Jean Pierre ^a,b,c   Waller, Chantal ^a,b,c   Kientz, Daniel ^a,b,c   Mendel, Isabelle ^a,b,c   Lin, Lily ^a,b,c   Jacquet, Michele ^a,b,c   Propst, Meisa ^a,b,c   Liu, Weiqun ^a,b,c   Corash, Laurence ^a,b,c   Sundin, David ^a,b,c   Defoin, Laurence ^a,b,c   Messe, Nathalie ^a,b,c   Osselaer, Jean Claude ^a,b,c  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b CERUS CORPORATION   (United States)

^c UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN;

ADULT; APHERESIS; ARTICLE; BLOOD DISEASE; BLOOD TRANSFUSION REACTION; CHILD; EUROPE; FEMALE; HUMAN; INCIDENCE; INFANT; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHOTOCHEMISTRY; PLASMA TRANSFUSION; SAFETY; ULTRAVIOLET A RADIATION; VITAL SIGN;

ADULT; BLOOD COMPONENT TRANSFUSION; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DISINFECTION; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFANT; MALE; MIDDLE AGED; PLASMA; PROSPECTIVE STUDIES; PSORALENS; ULTRAVIOLET RAYS;

EID: 77953088856     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2009.02579.x     Document Type: Article

References (26)

1. Singh Y, Sawyer L, Pinkoski L, Dupuis KW, Hsu JC, Lin L, Corash L. Photochemical treatment of plasma with amotosalen and UVA light inactivates pathogens while retaining coagulation function. Transfusion 2006 46 : 1168 77.
2. Grass JA, Hei DJ, Metchette K, Cimino GD, Wiesehahn GP, Corash L, Lin L. Inactivation of leukocytes in platelet concentrates by psoralen plus UVA. Blood 1998 91 : 2180 8.
3. Grellier P, Benach J, Labaied M, Charneau S, Gil H, Monsalve G, Alfonso R, Sawyer L, Lin L, Steiert M, Dupuis K. Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components. Transfusion 2008 48 : 1676 84.
4. Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001 38 Suppl 11 : 4 11.
5. Hambleton J, Wages D, Radu-Radulescu L, Adams M, Mackenzie M, Shafer S, Lee M, Smyers J, Wiesehahn G, Corash L. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002 42 : 1302 7.
6. de Alarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R, Smith P, Abshire T, Hambleton J, Matthew P, Ortiz I, Cohen A, Konkle BA, Streiff M, Lee M, Wages D, Corash L. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation (PCT-FFP): transfusion of patients with congenital factor deficiencies. Transfusion 2005 45 : 1362 72.
7. Mintz PD, Bass NM, Petz LD, Steadman R, Streiff M, McCullough J, Burks S, Wages D, Van-Doren S, Corash L. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006 107 : 3753 60.
8. Mintz PD, Neff A, MacKenzie M, Goodnough LT, Llyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Rouault C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan MG. A randomized, controlled phase III trial of therapeutic plasma exchange with fresh frozen plasma prepared with amotosalen and UVA light compared to untreated fresh frozen plasma in thrombotic thrombocytopenic purpura. Transfusion 2006 46 : 1693 704.
9. Andreu G, Morel P, Forestier F, Debeir J, Rebibo D, Janvier G, Herve P. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion 2002 42 : 1356 64.
10. Faber JC. Haemovigilance in Europe: now and tomorrow. In : Rouger P, Hossenlopp C, editors. Blood transfusion in Europe.
11. Schlenke P, Hervig T, Isola H, Wiesel ML, Kientz D, Pinkoski L, Singh Y, Lin L, Corash L, Cazenave JP. Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion 2008 48 : 697 705.
12. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008 48 : 1061 71.
13. Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De-Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padron F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008 94 : 315 23.
14. Ware L, Matthay M. The acute respiratory distress syndrome. N Engl J Med 2000 342 : 1334 49.
15. Council of Europe. Guide to the preparation, use and quality assurance of blood components. 13th ed.
16. MacLennan S, Barbara JA. Risks and side effects of therapy with plasma and plasma fractions. Best Pract Res Clin Haematol 2006 19 : 169 89.
17. Bettmann MA, Heeren T, Greenfield A, Goudey C. Adverse events with radiographic contrast agents: results of the SCVIR Contrast Agent Registry. Radiology 1997 203 : 611 20.
18. Alving B. Transfusion of the patient with acquired coagulation defects. In : Hillyer CD, Silberstein LE, Ness PM, Anderson KC, editors. Blood banking and transfusion medicine.
19. Rodgers GM, Greenberg CS. Inherited coagulation disorders. In : Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, editors. Wintrobe's clinical hematology.
20. Dodd RY. Current risk for transfusion transmitted infections. Curr Opin Hematol 2007 14 : 671 6.
21. Biggerstaff BJ, Petersen LR. Estimated risk of transmission of the West Nile virus through blood transfusion in the US, 2002. Transfusion 2003 43 : 1007 17.
22. Linnen JM, Vinelli E, Sabino EC, Tobler LH, Hyland C, Lee TH, Kolk DP, Broulik AS, Collins CS, Lanciotti RS, Busch MP. Dengue viremia in blood donors from Honduras, Brazil, and Australia. Transfusion 2008 48 : 1355 62.
23. Likos AM, Kelvin DJ, Cameron CM, Rowe T, Kuehnert MJ, Norris PJ National Heart, Lung, Blood Institute Retrovirus Epidemiology Donor Study-II (REDS-II). Influenza viremia and the potential for blood-borne transmission. Transfusion 2007 47 : 1080 8.
24. Brouard C, Bernillon P, Quatresous I, Pillonel J, Assal A, De-Valk H, Desenclos JC. Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005-2007. Transfusion 2008 48 : 1333 41.
25. Stainsby D, Jones H, Asher D, Atterbury C, Boncinelli A, Brant L, Chapman CE, Davison K, Gerrard R, Gray A, Knowles S, Love EM, Milkins C, McClelland DB, Norfolk DR, Soldan K, Taylor C, Revill J, Williamson LM, Cohen H SHOT Steering Group. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006 20 : 273 82.
26. Chapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, Navarrete C, Lucas G, Soni N, Morgan C, Choo L, Cohen H, Williamson LM Serious Hazards of Transfusion Steering Group. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009 49 : 440 52.